Centanafadine is a novel, first-in-class, non-stimulant under development for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It’s rapid onset & good safety profile would likely result in uptake for patients who do not respond to generic stimulant / non-stimulant therapy options.
A new formulation of lenacapavir has been developed for preexposure prophylaxis (PrEP) against HIV-1 infection. Yeztugo provides protection with only two annual injections. Gilead is also in the process of developing a once-yearly formulation of Yeztugo.
YESINTEK (ustekinumab-kfce)Manufacturer: BioconLaunch Date: 2/24/2025 SELARSDI (ustekinumab-aekn)Manufacturer: Alvotech/TevaLaunch Date: 1/2025 YESINTEK & SELARSDI are biosimilars of reference product STELARA (Ustekinumab),…
Neffy® (epinephrine nasal spray) was approved on August 9, 2024, for the emergency treatment of allergic reactions (type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients weighing at least 66 pounds.
On June 24, 2024, drug manufacturer Teva Pharmaceuticals announced the launch of an authorized generic formulation of Novo Nordisk’s Victoza (liraglutide). This marks the first generic glucagon-like peptide-1 (GLP-1) agonist available in the U.S. market.
On March 14, 2024, drug manufacturer Madrigal Pharmaceuticals announced the approval of Rezdiffra™, a new, first in class oral therapy for nonalcoholic steatohepatitis (NASH). This disease, which impacts an estimated 6-8 million people in the U.S., is underdiagnosed and if left untreated, it can cause serious liver complications. Read more about this approval and its implications.
On November 8, 2023, Eli Lilly announced the approval of the newest weight loss drug Zepbound, a much-anticipated formulation of tirzepatide in the high-profile GLP-1 agonist medications class. Used along with reduced calorie diet and exercise, studies have shown Zepbound can lead to significant weight loss.
In 2023, the U.S. Food & Drug Administration (FDA) approved three new vaccines for the prevention of Respiratory Syncytial Virus (RSV). RSV is a highly contagious, common respiratory virus that typically causes mild cold-like symptoms. However, it can cause serious illness in older adults and infants.
The launch of Amjevita, the first FDA-approved biosimilar for Humira, is big news for pharmacy benefit plan sponsors.